Rapamycin-treated malignant neuroblastoma SK-N-BE2 and IMR-32 xenogratfs were further subjected to CTL shRNA plasmid transfection, LC3 shRNA plasmid transfection, GST treatment, and LC3 shRNA plasmid transfection + GST treatment (Figure 7). The gene discussed is MAP1LC3A; the disease is neuroblastoma.